A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Active:	No
Cancer Type:	Multiple Myeloma Plasma cell neoplasm	NCT ID:	NCT02773030
Trial Phases:	Phase I Phase II	Protocol IDs:	CC-220-MM-001 (primary) NCI-2016-01463
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Celgene
NCI Full Details:	http://clinicaltrials.gov/show/NCT02773030

Summary

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study
consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in
combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with
DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D
(Part 2) for CC-220 monotherapy and CC-220 in combination with DEX for Relapsed
Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in
combination with DEX and DARA for Newly Diagnosed Multiple Myeloma (NDMM).

Objectives

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have
the option to receive DEX in addition to CC-220 after consultation with the Medical
Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in
combination with dexamethasone in Cohort B that has been determined to be safe.
Progressive disease must be confirmed in accordance with international myeloma working
group (IMWG) criteria.

For Cohorts A and B, the starting dose level of CC-220, dose level 1, is 0.3 mg. A dose
level -1, of 0.15 mg, may also be evaluated if the starting dose level of 0.3 mg for 21
days of a 28-day cycle is not tolerated. For Cohorts E and F, the starting dose level of
CC-220, dose level 1, is one dose level below the maximum dose for Cohort B that has been
determined to be safe by the dose escalation committee (DEC) at the start of enrollment
for both cohorts. For Cohort E in addition to CC-220 and DEX, daratumumab will be
administered intravenously (IV) at a 16mg/kg dose. For Cohort F in addition to CC-220 and
DEX, bortezomib will be administered subcutaneous (SC) at a 1.3mg/m2 dose.

All subjects who discontinue study treatment in Part 1 or Part 2 of the study for a
reason other than PD or withdrawal of consent from the study will be followed for
response assessment every 28 days (every 21 days for Cohort F) until PD.

The study will be conducted in compliance with the International Council for
Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for
Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.

The initiation of Part 2 will begin when the recommended phase 2 dose (RP2D) is
established in Part 1 in either Cohort A, Cohort B, Cohort E or Cohort F. The cohorts may
begin once the RP2D is determined for each cohort independently during Part 1. All
expansion decisions will be determined by the DEC after review of all safety, PK,
biomarker and preliminary efficacy data, as applicable. During Part 2, the Independent
Expert Reviewer will review safety data and any other data deemed relevant so that
subject safety is ensured.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.